|Molar Mass||426.853 g/mol|
|Trade Name||Lenvima, Lenvanix|
|Metabolism||Cyp3a4, Aldehyde Oxidase, Non-enzymatic|
Preferred Buyer From
|Location||All Countries Except India|
Lenvatinib is an anti-cancer drug for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.